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Aims Controversy exists regarding the importance of glycaemic control in patients with type 2 diabetes mellitus (T2DM)
and chronic heart failure (CHF) based on conflicting reports using single baseline glycosyated haemoglobin (HbA1c).
Using the time-weighted mean of serial HbA1c measurements has been found to be a better predictor of diabetic
complications as it reflects the glycaemic burden for that individual over time. We therefore sought to confirm this
in a large cohort of patients with T2DM and incident CHF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
A time-weighted mean HbA1c was calculated using all HbA1c measurements following CHF diagnosis. Patients were
grouped into five categories of HbA1c (≤6.0%, 6.1–7.0%, 7.1–8.0%, 8.1–9.0%, and >9.0%). The relationship between
time-weighted mean HbA1c and all-cause death after CHF diagnosis was assessed. A total of 1447 patients with T2DM
met the study criteria. During a median follow-up of 2.8 years, there were 826 (57.1%) deaths, with a crude death rate
of 155 deaths per 1000 person-years [95% confidence interval (CI) 144–166]. A Cox regression model, adjusted for
all significant predictors, with the middle HbA1c category (7.1–8.0%) as the reference, showed a U-shaped relationship
between HbA1c and outcome [HbA1c <6.0%, hazard ratio (HR) 2.5, 95% CI 1.8–3.4; HbA1c 6.1–7.0%, HR 1.4, 95%
1.1–1.7; HbA1c 8.1–9.0%, HR 1.3, 95% CI 1.0–1.6; and HbA1c >9.0%, HR 1.8, 95% CI 1.4–2.3]. Further analysis
revealed a protective effect of insulin sensitizers (i.e. metformin) (HR 0.7, 95% CI 0.61–0.93) but not other drug
classes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions In patients with T2DM and CHF, our study shows a U-shaped relationship between HbA1c and mortality, with the
lowest risk in patients with modest glycaemic control (HbA1c 7.1–8.0%) and those treated with insulin sensitizers.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Chronic heart failure (CHF) and type 2 diabetes mellitus (T2DM)
frequently co-exist. In population-based studies and in CHF trials,
the prevalence of T2DM is estimated to be between 11% and 28%.
Among all patients hospitalized for CHF, it has been reported that
25–30% have T2DM.1 This association can be lethal since T2DM
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.. has consistently been shown to be an independent predictor of
increased morbidity and mortality in patients with CHF.2
The question arises of whether glycaemic control matters in
T2DM patients with CHF. The benefit of improved glycaemic con-
trol on microvascular complications in T2DM is well established.
Trials have attempted to clarify the role of glycaemic control in
macrovascular outcomes.3,4 These data suggest that improved
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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glycaemic control has the potential to reduce significantly the risk
of both micro- and macrovascular disease when instigated early
in the disease course, but, in more advanced T2DM, the benefits
of improved control appear to be less evident.5 Furthermore,
studies suggest that tight glycaemic control can sometimes be
associated with a poorer macrovascular outcome.6,7 In patients
with co-existing CHF and T2DM, the relevance of good glycaemic
control is a critical issue not only as the combination may be asso-
ciated with a significantly poorer outcome but also as the choice
of drugs available to manage the hyperglycaemia in CHF is perhaps
more limited.8,9 There have been conflicting reports regarding
the importance of glycaemic control in patients with T2DM and
CHF.10–14 The level of glycosylated haemoglobin (HbA1c) provides
a measure of the glycaemic control of patients with T2DM during
the previous 2–3 months.15 Studies that assessed the importance
of glycaemic control in diabetic patients with CHF10–14 have usu-
ally used a single measurement of HbA1c which has been shown to
underestimate the importance of glycaemic control.16 Calculation
of a mean of serial HbA1c measurements has been found to be a
better predictor of diabetic complications,2,15,17 and this may be
due to the fact that it incorporates multiple measurements over
time2,16 and therefore better reflects the glycaemic burden for that
individual. However, this variable may also result in underestima-
tion of the importance of glycaemic control, as the updated mean
value of HbA1c gives equal weight to all historical HbA1c measure-
ments. However, a more accurate assessment of the effects of
HbA1c would be one that incorporates not only the HbA1c value
itself but also the length of time that the patient has been at that
level, thus accounting for the natural fluctuation of HbA1c as well as
its temporal effects on outcomes. This time-weighted mean HbA1c
method has been shown to be superior to the updated mean.18
We therefore sought to determine the relationship between the
time-weighted mean HbA1c and outcomes in a large cohort of
patients with T2DM and incident CHF.
Methods
Data sources
We exploited the established regional clinical informatics systems
developed in partnership between the University of Dundee and NHS
Tayside which makes use of a unique health record identifier, the Com-
munity Health Index (CHI) number, to link multiple clinical data sets
deterministically through established and robust anonymization pro-
tocols within the Health Informatics Centre (HIC) and the University
of Dundee at an individual level with high accuracy. The clinical data
sets include the following (i) Echocardiography Database: this contains
information on all clinically requested outpatient echocardiograms per-
formed in Ninewells Hospital, Dundee and is maintained by the Depart-
ment of Cardiology, Ninewells Hospital. All echocardiograms are per-
formed in a standardized protocol by accredited echo cardiographers.
(ii) Scottish Care Information–Diabetes Collaboration: the SCI-DC
data set contains detailed clinical information on every patient diag-
nosed with DM in Tayside. Clinical information is collected according
to the national clinical data set for the care of diabetic patients in
Scotland and includes diabetes type and date of diagnosis. (iii) Other
HIC data sets: other data sets utilized were the dispensed prescribing ..
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.. data set which contains detailed information of all prescription drugs
that are dispensed for essentially all individuals in Tayside over the
past 20 years. Hospital discharge data comprising the Scottish Morbid-
ity Record (SMR01) containing International Classification of Diseases
(ICD) 9 and 10 classification codes, data on death from the General
Registrar’s Office (GRO), and finally laboratory data containing infor-
mation on all biochemical tests on all individuals historically. Access to
the anonymized data sets was approved by the East of Scotland Ethics
Committee.
Study design
We performed a retrospective observational cohort study between 1
January 1993 and 31 March 2010 in Tayside Scotland (population 400
000) to examine the relationship between HbA1c and all-cause death
in patients with T2DM who subsequently develop CHF. Therefore, to
be eligible for the study, patients had to develop incident CHF after
being diagnosed with T2DM. The patients also had to have at least one
HbA1c measurement recorded after CHF diagnosis.
Definition of chronic heart failure
Chronic heart failure was defined as a record of an echocardiogram
with evidence of LV systolic dysfunction and, either a prescription
for a loop diuretic (British National Formulary code 2.2.2; provided
not greater than 1 year prior to echocardiogram) or an admission to
hospital with an associated CHF diagnostic code (ICD9 428, ICD10
I50). We used these ICD CHF diagnostic codes based on previous
work that had demonstrated their validity in identifying HF from
electronic records.19–21 With respect to the CHF definition based on
the prescription of a loop diuretic, a previous case validation exercise
found 91% concordance between a clinical diagnosis of HF from case
note review and definition of HF based on echocardiographic evidence
of LV systolic dysfunction requiring prescription of loop diuretics.22
Definition of study period
Immortal time bias can affect observational cohort studies when
improper design or analysis methods are used.23 In order to account
for immortal time, we only considered each individual to be at risk at
the time when they met all the CHF diagnostic criteria and had their
first HbA1c measurement. We adjusted for the time between initial
CHF diagnosis (baseline) and first Hba1c measurement in our model.
Calculation of mean glycosylate
haemoglobin
A time-weighted mean HbA1c was calculated using all available HbA1c
measurements during the ‘at-risk’ period. The mean was weighted by
time between measurements and was then used to group patients into
five categories of HbA1c (≤6.0%, 6.1–7.0%, 7.1–8.0%, 8.1–9.0, and
>9.0%).
Covariates
In the models, the following covariates were considered in addition to
mean study HbA1c: age at T2DM diagnosis, sex, and social deprivation;
and the following baseline measures: age, weighted mean of available
HbA1c measurements from DM diagnosis to baseline, smoking status,
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and prior hospitalization with myocardial infarction (MI) (defined as
ICD9 410–414, ICD10 I21–I25). For mean body mass index (BMI),
mean arterial pressure (MAP), and estimated glomerular filtration
rate (eGFR), we utilized all available measurements up to 2 years
prior to baseline. Any prescriptions up to 6 months prior to base-
line for DM treatment grouped by diet alone, insulin sensitizers,
insulin secretagogues, and insulin, and cardiovascular medication
[aspirin, statins, thiazide diuretics, beta-blockers, ACE inhibitors or
ARBs, and calcium channel blockers (CCBs) (split by rate-limiting
and all others)] were used to define drug use at baseline. During
the study period, hospitalization with MI, and prescriptions for DM
and cardiovascular medication were entered into the model time
dependently.
Statistical analysis
A Cox proportional hazards model with delayed entry was used to
model time to death.18,24 Time from CHF diagnosis was assessed, with
patients entering the risk set at the date of their first HbA1c after CHF
diagnosis. For each model, all covariates were entered, then backward
elimination was performed with any covariates with a significance of
P> 0.05 excluded from the final model. Time-dependent covariates
were modelled by splitting the follow-up into 56-day intervals, which
corresponded to the median duration of drug prescription. This
method allows us to observe any changes in the patient’s circumstances
in every interval, updating the changes in all the covariates during
that same period. Any HbA1c reading that was detected was then
weighted to the time duration from the previous reading. Unadjusted
models are also presented. In the analysis split by diet and drug
treatment, to enable the inclusion of all patients, drug treatment was
defined as any treatment between date of T2DM diagnosis and study
end. All tests were two-sided, with a P-value of <0.05 considered
significant. All statistical analysis were performed using R for windows
(v3.2.0)
Results
From an initial 2035 T2DM subjects in the echocardiographic
database with evidence of LV systolic dysfunction following DM
diagnosis, 1933 (95%) had a post-DM diagnosis hospitalization for
CHF and/or valid loop diuretic prescription. Of those, 1447 had an
HbA1c measurement during their observable study period.
Characteristics of the 1447 patients in the study population
are provided in Table 1 split by HbA1c category. Patients in the
lowest HbA1c category had shorter study duration and therefore
fewer HbA1c measurements, were diagnosed with CHF and T2DM
at an older age, and had a lower BMI and eGFR at baseline. In
addition, although not statistically significant, they tended to be
more likely to smoke and were prescribed less aspirin but had
fewer MI events prior to baseline.With respect to diabetes therapy,
there were relatively more diet-treated and fewer insulin-treated
patients.
In contrast, patients in the highest HbA1c category were diag-
nosed with CHF and T2DM at a younger age, had a higher BMI
and eGFR, relatively more MI events at baseline, and comprised
the smallest proportion of diet- and the largest proportion of
insulin-treated patients. In addition, they were more likely to be
prescribed aspirin at baseline. ..
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.. Glycosylated haemoglobin and mortality
Over a median follow-up of 2.8 years, there were 826 (57%)
all-cause deaths, with a crude death rate of 155 deaths per 1000
person-years. In a Cox regression model, adjusted for all other
significant predictors, with the middle HbA1c category (7.1–8%)
as the reference, we found a U-shaped relationship between
HbA1c and outcome, with the two lowest and the highest HbA1c
categories significantly associated with a higher risk of death:
HbA1c <6.0%, hazard ratio (HR) 2.5, 95% confidence interval
(CI) 1.8–3.4; HbA1c 6.1–7.0%, HR 1.4, 95% CI 1.1–1.7; HbA1c
8.1–9.0%, HR 1.3, 95% CI 1.0–1.6; and HbA1c >9.0%, HR 1.8,
95% CI 1.4–2.3 (Figure 1). (The full model is included in the
Supplementary material online, Table S1.)
Glycosylated haemoglobin and mortality:
diet- and drug-treated type 2 diabetes
To explore this U-shaped association more carefully, we limited
our analysis to the lower two categories of HbA1c <6.0% and
6.1–7.0% (i.e. HbA1c ≤7%) comparing patients on diet and drug
treatment (Table 2). We made two observations in the analysis
of this subgroup. First, when comparing HbA1c levels before and
after CHF diagnosis, there was no difference in the diet-treated
group (mean± SD, 6.11± 0.81 vs. 6.11± 0.55, P= 0.29) but in
the drug-treated group the HbA1c was significantly lower after
CHF diagnosis (7.27± 1.1 vs. 6.33± 0.49, P< 0.0001), indicating
an intensification of treatment following the diagnosis of CHF
(Table 2). Secondly, we, unexpectedly, found patients on diabetic
medications to have higher mortality than those who were not
(HR 1.5, 95% CI 1.2–2.0).
We then studied the relationship between HbA1c and death
(for the entire study population) in the diet- and drug-treated
groups separately. As the number of patients in each group became
smaller, we reduced the number of HbA1c categories to three
(≤7%, 7.1–9%, and >9%). The adjusted and unadjusted Cox
regression models are presented in Table 3 (full models included in
the Supplementary material online, Tables S2–S4). The U-shaped
association observed in the overall study population remained in
the drug-treated group, but was lost in the diet-controlled group
(Figure 2A and B) This, once again, suggested the increased mortality
of patients at low HbA1c levels seen in the overall model to be the
result of diabetic drug therapy. Finally, we developed an adjusted
model for the drug-treated group alone and saw a significant
protective effect of exposure to metformin (HR 0.75, 95% CI
0.61–0.93), but not in patients on insulin secretagogues (such as
sulphonylureas) or insulin.
Discussion
This study had two main findings. First, in our cohort of T2DM
patients with incident CHF, we observed a U-shaped relation-
ship between mortality and glycaemic control, as assessed by a
time-weighted mean HbA1c. Secondly, additional analysis showed
that this U-shaped relationship was present in drug-treated but
not in diet-treated T2DM patients. A closer inspection of the
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Clinical characteristics by glycosylated haemoglobin category
All HbA1c category (%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
<6 6.1–7.0 7.1–8.0 8.1–9.0 >9
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number of subjects (%) 1447 (100.0) 171 (11.8) 411 (28.4) 415 (28.7) 237 (16.4) 213 (14.7)
Age (years) 71.8(9.95) 73.5 (9.52) 73.6 (9.84) 72 (9.49) 70.6 (9.69) 68.1 (10.5) 0.078b
Females (%) 551 (38.1) 64 (37.4) 142 (34.5) 169 (40.7) 96 (40.5) 80 (37.6) 0.399a
Total follow up time
(person-years)
5334 459 1385 1750 1010 729
Deaths (%) 826 (57.1) 109 (63.7) 214 (52.1) 242(58.3) 140 (59.1) 121 (56.8)
Death rate/1000
person-years (95% CI)
155 (144–166) 237 (195–286) 154 (134–177) 138 (121–157) 139 (117–164) 166 (138–198)
Age at DM diagnosis 62.5 (11.8) 65.6 (11.2) 66.2 (10.8) 62.3 (11.3) 59.0 (11.9) 57.1 (11.7) 0.002b
Duration of diabetes (years) 7.7 (3.5, 13.2) 5.4 (2.4, 10.6) 5.7 (2.35, 10.6) 8.1 (3.72, 14) 10.1 (5.9, 15.6) 9.9 (5.4, 15.6) 0.001c
MAP (mmHg) 96.3 (50) 94.6 (13) 96.3 (14) 95.7 (13) 97.6 (5) 97.4 (5) 0.385b
BMI 29.1 (25.7, 33) 26.8 (24, 31.6) 28.7 (25.5, 32.3) 28.9 (25.8, 33) 29.5 (26.4, 33.1) 31 (27.1, 34.8) 0.003c
eGFR (ml/min/1.72m2) 58.6 (12) 53.9 (1) 59.3 (3) 57.5 (5) 59.3 (2) 62.3 (1) 0.107b
Number of post-CHF HbA1c
measurements
8 (3–16) 4 (2–9) 7 (2–14) 9 (4–19) 9 (4–21) 8 (4–15) <0.0001c
Mean HbA1c prior to CHF
diagnosis
7.57 (1.43) 6.52 (1.27) 7.03 (1.06) 7.69 (1.36) 8.16 (1.44) 8.56 (1.3) <0.0001c
Mean HbA1c after CHF
diagnosis
7.53 (1.43) 5.59 (0.329) 6.53 (0.277) 7.47 (0.285) 8.47 (0.289) 10.1 (1.01) <0.0001c
Ever smoked 791 (54.7) 92 (53.8) 245 (59.6) 221 (53.3) 123 (51.9) 110 (51.6) 0.166a
Previous MI 703 (48.6) 74 (43.3) 205 (49.9) 193 (46.5) 124 (52.3) 107 (50.2) 0.345a
Social deprivation: 0.495a
1 (most) 362 (25) 44 (25.7) 93 (22.6) 106 (25.5) 59 (24.9) 60 (28.2)
2 256 (17.7) 30 (17.5) 66 (16.1) 73 (17.6) 48 (20.3) 39 (18.3)
3 254 (17.6) 37 (21.6) 73 (17.8) 64 (15.4) 37 (15.6) 43 (20.2)
4 358 (24.7) 40 (23.4) 104 (25.3) 108 (26) 63 (26.6) 43 (20.2)
5 (least) 199 (13.8) 17 (9.9) 69 (16.8) 58 (14) 28 (11.8) 27 (12.7) .
Diabetic therapy
Diet control 355 (24.5) 82 (48.0) 124 (30.2) 98 (23.6) 30 (12.7) 21 (9.9) <0.0001a
Insulin sensitizers 524 (36.2) 37 (21.6) 153 (37.2) 153 (36.9) 90 (38) 91 (42.7) <0.0001a
Insulin secretagogues 554 (38.3) 45 (26.3) 150 (36.5) 163 (39.3) 111 (46.8) 85 (39.9) <0.0001a
Insulin 354 (24.5) 19 (11.1) 55 (13.4) 98 (23.6) 88 (37.1) 94 (44.1) <0.0001a
Cardiovascular drugs
ACE-I / ARB 843 (58.3) 98 (57.3) 236 (57.4) 242 (58.3) 132 (55.7) 13 5 (63.4) 0.538a
Beta-blockers 527 (36.4) 59 (34.5) 164 (39.9) 143 (34.5) 77 (32.5) 84 (39.4) 0.237a
Thiazide diuretics 131 (9.1) 15 (8.8) 46 (11.2) 34 (8.2) 12 (5.1) 24 (11.3) 0.074a
Statins 744 (51.4) 84 (49.1) 216 (52.6) 213 (51.3) 114 (48.1) 117 (54.9) 0.615a
Aspirin 787 (54.4) 83 (48.5) 236 (57.4) 214 (51.6) 134 (56.5) 120 (56.3) 0.200a
Rate-limiting CCB 155 (10.7) 19 (11.1) 42 (10.2) 47 (11.3) 23 (9.7) 24 (11.3) 0.961a
Non-rate-limiting CCB 347 (24) 44 (25.7) 90 (21.9) 97 (23.4) 66 (27.8) 50 (23.5) 0.505a
BMI, body mass index; CCB, calcium channel blocker; CHF, chronic heart failure; CI, confidence interval; DM diabetes mellitus; eGFR, estimated glomerular filtration rate;
HbA1c, glycosylated haemoglobin; MAP, mean arterial pressure; MI, myocardial infarction.
a.Chi-square;
b.ANOVA;
c.Mann-Whitney test.
drug-treated group revealed a clear difference in the outcomes
driven by the type of antidiabetic therapy; patients on ‘low hypo-
glycaemia risk’ medications had fewer outcomes than those on
‘high hypoglycaemia risk’ medications (insulin secreatagougues or
insulin).
The relationship between glycaemic control and outcome in
patients with CHF and T2DM has previously been studied in ..
..
..
..
..
..
..
..
..
.. at least four retrospective studies, with different conclusions
reported.11–14 The relationship between glycaemic control and
outcome has been reported to be ‘U’ shaped,14, ‘J’ shaped,13
linear,12 and even inverse.11 In the most recent analysis, Aguilar
et al.14 performed a retrospective analysis of 5815 veterans (94%
male) with T2DM and CHF defined by clinic coding, 45.5% of which
had significantly impaired LV function. Over a 2-year follow-up
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
98 D.H.J. Elder et al.
Figure 1 Hazard ratios for death by categories of glycosylated haemoglobin (HbA1c).
they observed a U-shaped relationship between HbA1c and mor-
tality, with a ‘sweet spot’ seen with individuals in quintile 3 (HbA1c
7.1–7.8 %). Compared with quintile 3, all other quintiles had sig-
nificantly elevated risk of death at 2 years, with those in the lowest
and highest quintiles faring worst. Our data would support these
findings. It should be noted that, like most of the previous studies,
Aguilar’s study used only a single HbA1c measurement to assess
glycaemic control. However, a single HbA1c may not be reliable,
especially if sampled at the time of the diagnosis of CHF when it is
potentially influenced by recent alterations in therapy. Individuals
may consult physicians with symptoms prior to diagnosis, leading
to alterations in oral hypoglycaemic agents or initiation of diuretic
therapy that may affect the single HbA1c measurement recorded in
the specialist clinic at the time of CHF diagnosis. This effect was
clearly demonstrated in our cohort when we observed a signif-
icant improvement in HbA1c levels among drug-treated patients
following the diagnosis of CHF, indicating an intensification of ther-
apy at the time of diagnosis. In addition to that, studies have also
shown that HbA1c levels have a persistent association with com-
plications several years after their measurement.25,26 Our data
are unique as we were able to utilize all HbA1c measurements
recorded for each individual, enabling us to consider the impor-
tance of longer term glycaemic control over a long period of time
in a large patient cohort. In this study, we used a time-weighted
mean to examine the impact of glycaemic control on outcome.
This method of HbA1c analysis has been shown to offer supe-
rior predictive power over time when compared with a single
baseline measurement which, as we have shown, can result in
underestimations of the impact of glycaemic control.2,16,27 It should
be noted that others have attempted to achieve the same effect
by using techniques such as simple mean, logarithm of updated
means, annual average change slope, and change between baseline
and final measures, none of which has been shown to be supe-
rior to the time-weighted mean.17,28 Although they may appear
to incorporate multiple measurements of HbA1c, they all discount
the important component of time weightage. Multiple studies have .
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. shown a legacy effect of HbA1c where it can have an influence
on outcomes remote from the time of measurement.29,30 Merely
accounting for fluctuations in HbA1c without factoring in its tem-
poral relationship to outcomes is too simplistic and has been
shown to result in suboptimal analysis.31,32 Accordingly, the use
of time-weighted mean HbA1c coupled with a median follow-up of
2.8 years enhances the ability of this study to determine accurately
the relationship between HbA1c and mortality, as the predictive
power of mean HbA1c is known to increase with longer study
length.25–27
The finding of a higher mortality risk in patients in the lower
HbA1c categories (HbA1c ≤6% and HbA1c 6.1–7%) deserves some
consideration. In our study, patients in these low HbA1c categories
had both favourable and less favourable clinical characteristics.
On the one hand, these patients had fewer previous MIs and
had less intensive DM treatment with less use of insulin. On the
other hand, these patients were older when they developed their
CHF and they had a lower eGFR. Interpretation of these findings
is always going to be limited by a lack of information on the
underlying cause of death. However, our finding that this U-shaped
relationship was present in drug-treated but not in diet-treated
T2DM patients may suggest that the outcomes observed in the
low HbA1c categories may be related to the response of patients to
the DM medications. It should be noted that the current findings
are concordant with the ACCORD5 study which demonstrated
that very tight control of glucose in patients with T2DM may
not be beneficial in those with existing cardiovascular disease
and a longer duration of T2DM. Besides that, further analysis of
the results from the Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study (EPHESUS) trial also
revealed a similar finding of poorer outcomes among patients
with hypoglycaemia complicating HF post-MI (HR 1.38, 95% CI
1.06–1.81).33 There are multiple pathophysiological mechanisms
that are implicated in hypoglycaemia-induced cardiovascular events.
A key mechanism revolves around the profound sympatho-adrenal
system activation resulting in a surge in catecholamines. In an
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Mean HbA1c and mortality in CHF 99
Table 2 Clinical characteristics of glycosylated haemoglobin ≤7% split by diabetes treatment
All Diet control Anti-DM drugs P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number of subjects (%) 582 (100) 206 (35.4) 376 (64.6) .
Age 73.6 (9.74) 74.2 (9.95) 73.3 (9.62) 0.316b
Females 206 (35.4) 77 (37.4) 129 (34.3) 0.516a
Total follow up time (person-years) 1844 737 1107 .
Deaths (%) 323 (55.5) 116 (56.3) 207 (55.0)
Death rate/1000 person-years (95% CI) 175 (156–195) 157 (130–189) 187 (162–214)
Age at DM diagnosis 66.2 (2) 69 (1) 64.6 (1) <0.0001b
Duration of diabetes (years) 5.6 (2.4, 10.6) 3.15 (1.52, 6.45) 7.3 (3.45, 12.2) <0.0001c
MAP (mmHg) 95.8 (14.1) 96.4 (14.1) 95.5 (14.1) 0.511b
BMI 28.9 (5.7) 27.7 (5.5) 29.5 (5.7) 0.001b
eGFR (ml/min/1.72m2) 57.7 (23.8) 55.9 (23.1) 58.7 (24.2) 0.169b
Mean HbA1c prior to CHF diagnosis 6.88 (1.15) 6.11 (0.81) 7.27 (1.1) <0.0001
c
Mean HbA1c after CHF diagnosis 6.25 (0.52) 6.11 (0.55) 6.33 (0.49) <0.0001
b
Ever smoked 337 (57.9) 121 (58.7) 216 (57.4) 0.892a
Previous MI 279 (47.9) 98 (47.6) 181 (48.1) 0.965a
Social deprivation
1 (most) 137 (23.5) 45 (21.8) 92 (24.5) 0.922a
2 96 (16.5) 37 (18) 59 (15.7)
3 110 (18.9) 39 (18.9) 71 (18.9)
4 144 (24.7) 51 (24.8) 93 (24.7)
5 (least) 86 (14.8) 32 (15.5) 54 (14.4)
Cardiovascular drugs
ACE-I / ARB 334 (57.4) 102 (49.5) 232 (61.7) 0.006a
Beta-blockers 223 (38.3) 78 (37.9) 145 (38.6) 0.939a
Thiazide diuretics 61 (10.5) 17 (8.3) 44 (11.7) 0.247a
Statins 300 (51.5) 100 (48.5) 200 (53.2) 0.324a
Aspirin 319 (54.8) 107 (51.9) 212 (56.4) 0.346a
Rate-limiting CCB 61 (10.5) 19 (9.2) 42 (11.2) 0.554a
Non-rate-limiting CCB 134 (23) 45 (21.8) 89 (23.7) 0.691a
ACE-I, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; CHF, chronic heart failure; CI,
confidence interval; DM diabetes mellitus; eGFR, esti8mated glomerular filtration rate; HbA1c, glycosylated haemoglobin; MAP, mean arterial pressure; MI, myocardial infarction.
Data are mean (standard deviation), median (interquartile range) or n(%).
a.Chi-square;
b.ANOVA;
c.Mann-Whitney test.
Table 3 Cox models analysing glycosylated haemoglobin by three categories
HbA1c category All (n=1447) Diet only (n= 328) DM drug (n= 1119)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adjusted
HR (95% CI)
Unadjusted
HR
Adjusted HR
(95% CI)
Unadjusted
HR
Adjusted HR
(95% CI)
Unadjusted
HR
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
≤7.0 1.4 (1.2–1.7) 1.2 (1.1–1.4) 1.09 (0.76–1.58) 1.2 (0.84–1.6) 1.5 (1.2–1.8) 1.3 (1.1–1.6)
7.1–9.0 1 1 1 1 1 1
>9.0 1.6 (1.3–2.0) 1.7 (1.4–2.0) 6.5 (2.8–14.8) 2.1 (1.1–4.1) 1.7 (1.3–2.1) 1.6 (1.2–2.0)
CI, confidence interval; HbA1c, glycosylated haemoglobin; HR, hazard ratio; DM, diabetes mellitus.
attempt to preserve the glucose supply to critical organs such
as the brain, blood is diverted cephalically and to the splanchnic
system (for gluconeogenesis in the liver) by increasing peripheral
vascular resistance and augmenting cardiac contractility and rate.34
Additionally there is also evidence of increased occurrence of
myocardial ischaemia35 and prolonged QT36 intervals during states .
..
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..
..
.. of hypoglycaemia among patients with T2DM. All of these may be
tolerated by diabetic patients without cardiovascular disease but
not those with concomitant CHF. These cardiac stressors, even
though transient, will only serve to accelerate decline in cardiac
function. All or a combination of these cardiac abnormalities
associated with hypoglycaemia could very well be the reason
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Figure 2 Hazard ratios for death by categories of glycosylated haemoglobin (HbA1c) among patients (A) on antidiabetic therapy and (B) on
diet control only.
behind our findings, indeed even those of larger trials such as
ADVANCE7, VADT,37 and ACCORD5.
In our study, we also observed a poor outcome in CHF
patients with the highest HbA1c. In a sense, this was not unex-
pected. These patients had more previous MIs at baseline, had
more aggressive DM therapy, with the largest proportion of
insulin-treated patients. These findings of worse outcomes among
patients with poor glycaemic control has been well described in
the contemporary literature38 and is concordant with previous
experimental work.39,40 Obviously, the mechanisms for reduced
survival associated both with very tight glycaemic as well with poor
glycaemic control in CHF must remain speculative and cannot be
inferred directly from this study.
We also made some expected observations regarding the effects
of medications on outcomes in this cohort of patients. Reassuringly,
we found patients on insulin sensitizers such as metformin to have
a lower mortality risk than those who were not. This echoes pre-
vious findings by our group on the beneficial effects of metformin
on a host of cardiovascular outcomes such as exercise capacity41
and mortality,42 as well as ongoing work on its effects on LV mass.43
There is also a large body of work that clearly demonstrates the .
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. beneficial effects of metformin in a heterogeneous group of patients
with high cardiovascular risk.44–46 These findings underscore not
only the safety but also the efficacy of metformin use in diabetic
patients with concomitant CHF. With respect to insulin use in CHF
patients, there are conflicting outcome data. Although patients with
T2DM on insulin had a higher risk of death in CHF trials,12,47 the
UKPDS 33 study48 as well as a retrospective cohort study of 16 000
Medicare diabetic beneficiaries with CHF, showed that insulin use
did not predict mortality.49 A potentially revealing analysis would
have been to determine if there were any differences in the out-
comes of patients treated with metformin vs. sulphonylurea/insulin
therapies within the lower HbA1c categories (i.e. HbA1c <7%). We
were unable to perform such an analysis in our cohort due to the
small numbers in this group (n= 376, before subdivision into treat-
ment categories); however, we believe future research in this area
should consider studying this.
Limitations
We recognize the limitations of our study that are inherent with
any retrospective, non-randomized, observational data. However,
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the current study reflects the true population and a ‘real world
scenario’ and adds to previous studies by selecting a large num-
ber of patients with T2DM and CHF with a long follow-up period.
In common with all observational studies, it was impossible in
our study to account for all confounding influences that may have
biased the observed differences between the groups considered.
We have sought to minimize these as far as practicable by uti-
lizing multivariate models and incorporating data on drug pre-
scribing, laboratory blood tests, and smoking status. Addition-
ally, because of the observational nature of this study, we were
unable to include patients with asymptomatic LV systolic dysfunc-
tion (Stage B heart failure), as these patients would not have been
routinely referred for echocardiographic assessment, and therefore
would be grossly under-represented. This study was also unable
to account for patients with HFpEF because of the inherent diffi-
culties in diagnosing HFpEF, supported by the lack of uniformity
between guidelines.50 Furthermore, we utilized multiple HbA1c
measurements for each individual, and as these were not sam-
pled at specified intervals this may potentially result in bias for
those who have a greater number of measures; in turn this was
minimized by utilizing a mean HbA1c weighted for time. Due to
the frequency of recording of renal function and BMI, we utilized
a mean value in our model. We were also unable to use con-
temporary biomarkers to diagnose and prognosticate HF such as
BNP because it is not a routinely available test in Tayside. The
study has considerable strengths, including the large number of
subjects, the large number of HbA1c measurements available, the
high event rate (62% mortality), and the reliable and comprehen-
sive data which were available with which to build the statistical
model.
Conclusion
In patients with T2DM and CHF, our observational study shows
that there is a U-shaped relationship between HbA1c and mortal-
ity, with the lowest mortality risk in patients with modest glycaemic
control (HbA1c, 7.1–8.0%). We also demonstrated low hypogly-
caemia risk medications such as metformin to be safe and effi-
cacious in this cohort. These observational data add support to
the growing concern that we need to redefine the optimal HbA1c
level and treatment choices in this high-risk group of patients with
co-existing T2DM and CHF.
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